Plant-produced Microbial Vaccines
Alexander V. Karasev
āĻāĻĒā§ā§°āĻŋāĻ˛ ā§¨ā§Ļā§Ļā§¯ ¡ Current Topics in Microbiology and Immunology āĻāĻŋāĻ¤āĻžāĻĒ 332 ¡ Springer Science & Business Media
ā§Ģ.ā§Ļstar
ā§§ āĻāĻž āĻĒā§°ā§āĻ¯āĻžāĻ˛ā§āĻāĻ¨āĻžreport
āĻāĻŦā§āĻ
120
āĻĒā§āĻˇā§āĻ āĻž
reportāĻŽā§āĻ˛ā§āĻ¯āĻžāĻāĻāĻ¨ āĻā§°ā§ āĻĒā§°ā§āĻ¯āĻžāĻ˛ā§āĻāĻ¨āĻž āĻ¸āĻ¤ā§āĻ¯āĻžāĻĒāĻ¨ āĻā§°āĻž āĻšā§ā§ąāĻž āĻ¨āĻžāĻ  āĻ
āĻ§āĻŋāĻ āĻāĻžāĻ¨āĻ
āĻāĻ āĻāĻŦā§āĻāĻāĻ¨ā§° āĻŦāĻŋāĻˇā§ā§
In recent years, plants have been increasingly explored for production of biomedicines and vaccine components. The two main advantages of plant systems are low cost and a greater potential for scalability as compared to microbial or animal systems. An additional advantage from the public health point of view is high safety compared to animal systems, which is important for vaccine production: there are no known plant pathogens capable of replicating in animals, and in humans in particular. A particular antigen or a protein has to be expressed in a plant using one of many available platforms; this antigen/protein subsequently needs to be purified or processed, and later formulated into a vaccine or a therapeutic; these need to be delivered to a human or animal body via an appropriate route. Naturally, all these vaccines and therapeutics must be subjected to regulatory approvals prior to their use. Thus, the challenge is to adapt plant-based platforms for production of cost-efficient biomedicals that can be approved by FDA for use as vaccine components or therapeutics which will be competitive against existing vaccines and drugs.
This volume attempts to address the entire spectrum of challenges facing the nascent field of plant-based biomedicals, from the selection of an appropriate production platform to specific methods of downstream processing and regulatory approval issues.
āĻŽā§āĻ˛ā§āĻ¯āĻžāĻāĻāĻ¨ āĻā§°ā§ āĻĒā§°ā§āĻ¯āĻžāĻ˛ā§āĻāĻ¨āĻžāĻ¸āĻŽā§āĻš
ā§Ģ.ā§Ļ
ā§§ āĻāĻž āĻĒā§°ā§āĻ¯āĻžāĻ˛ā§āĻāĻ¨āĻž
āĻāĻ āĻāĻŦā§āĻāĻāĻ¨āĻ āĻŽā§āĻ˛ā§āĻ¯āĻžāĻāĻāĻ¨ āĻā§°āĻ
āĻāĻŽāĻžāĻ āĻāĻĒā§āĻ¨āĻžā§° āĻŽāĻ¤āĻžāĻŽāĻ¤ āĻāĻ¨āĻžāĻāĻāĨ¤
āĻĒāĻĸāĻŧāĻžā§° āĻ¨āĻŋāĻ°ā§āĻĻā§āĻļāĻžā§ąāĻ˛ā§
āĻ¸ā§āĻŽāĻžā§°ā§āĻāĻĢâāĻ¨ āĻā§°ā§ āĻā§āĻŦāĻ˛ā§āĻ
Android āĻā§°ā§ iPad/iPhoneā§° āĻŦāĻžāĻŦā§ Google Play Books āĻāĻĒāĻā§ āĻāĻ¨āĻˇā§āĻāĻ˛ āĻā§°āĻāĨ¤ āĻ āĻ¸ā§āĻŦāĻ¯āĻŧāĻāĻā§āĻ°āĻŋāĻ¯āĻŧāĻāĻžā§ąā§ āĻāĻĒā§āĻ¨āĻžā§° āĻāĻāĻžāĻāĻŖā§āĻā§° āĻ¸ā§āĻ¤ā§ āĻāĻŋāĻāĻ āĻšāĻ¯āĻŧ āĻā§°ā§ āĻāĻĒā§āĻ¨āĻŋ āĻ¯'āĻ¤ā§ āĻ¨āĻžāĻĨāĻžāĻāĻ āĻ¤'āĻ¤ā§āĻ āĻā§āĻ¨ā§ āĻ
āĻĄāĻŋāĻ
'āĻŦā§āĻ āĻ
āĻ¨āĻ˛āĻžāĻāĻ¨ āĻŦāĻž āĻ
āĻĢāĻ˛āĻžāĻāĻ¨āĻ¤ āĻļā§āĻ¨āĻŋāĻŦāĻ˛ā§ āĻ¸ā§āĻŦāĻŋāĻ§āĻž āĻĻāĻŋāĻ¯āĻŧā§āĨ¤
āĻ˛ā§āĻĒāĻāĻĒ āĻā§°ā§ āĻāĻŽā§āĻĒāĻŋāĻāĻāĻžā§°
āĻāĻĒā§āĻ¨āĻŋ āĻāĻŽā§āĻĒāĻŋāĻāĻāĻžā§°ā§° ā§ąā§āĻŦ āĻŦā§āĻ°āĻžāĻāĻāĻžā§° āĻŦā§āĻ¯ā§ąāĻšāĻžā§° āĻā§°āĻŋ Google PlayāĻ¤ āĻāĻŋāĻ¨āĻž āĻ
āĻĄāĻŋāĻ
'āĻŦā§āĻāĻ¸āĻŽā§āĻš āĻļā§āĻ¨āĻŋāĻŦ āĻĒāĻžā§°ā§āĨ¤
āĻ-ā§°ā§āĻĄāĻžā§° āĻā§°ā§ āĻ
āĻ¨ā§āĻ¯ āĻĄāĻŋāĻāĻžāĻāĻ
Kobo eReadersā§° āĻĻā§°ā§ āĻ-āĻāĻŋā§āĻžāĻāĻšā§ā§° āĻĄāĻŋāĻāĻžāĻāĻāĻ¸āĻŽā§āĻšāĻ¤ āĻĒā§āĻŋāĻŦāĻ˛ā§, āĻāĻĒā§āĻ¨āĻŋ āĻāĻāĻž āĻĢāĻžāĻāĻ˛ āĻĄāĻžāĻāĻ¨āĻ˛âāĻĄ āĻā§°āĻŋ āĻ¸ā§āĻāĻā§ āĻāĻĒā§āĻ¨āĻžā§° āĻĄāĻŋāĻāĻžāĻāĻāĻ˛ā§ āĻ¸ā§āĻĨāĻžāĻ¨āĻžāĻ¨ā§āĻ¤ā§°āĻŖ āĻā§°āĻŋāĻŦ āĻ˛āĻžāĻāĻŋāĻŦāĨ¤ āĻ¸āĻŽā§°ā§āĻĨāĻŋāĻ¤ āĻ-ā§°āĻŋāĻĄāĻžā§°āĻ˛ā§ āĻĢāĻžāĻāĻ˛āĻā§ āĻā§āĻ¨ā§āĻā§ āĻ¸ā§āĻĨāĻžāĻ¨āĻžāĻ¨ā§āĻ¤ā§° āĻā§°āĻŋāĻŦ āĻāĻžāĻ¨āĻŋāĻŦāĻ˛ā§ āĻ¸āĻšāĻžāĻ¯āĻŧ āĻā§āĻ¨ā§āĻĻā§ā§°āĻ¤ āĻĨāĻāĻž āĻ¸āĻŦāĻŋāĻļā§āĻˇ āĻ¨āĻŋā§°ā§āĻĻā§āĻļāĻžā§ąāĻ˛ā§ āĻāĻžāĻāĻāĨ¤
